<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004084</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067295</org_study_id>
    <secondary_id>R01CA067026</secondary_id>
    <secondary_id>CMMI-C-037A-97</secondary_id>
    <secondary_id>NCI-H99-0041</secondary_id>
    <secondary_id>NCI-V99-1567</secondary_id>
    <nct_id>NCT00004084</nct_id>
  </id_info>
  <brief_title>Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia</brief_title>
  <official_title>Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immu-LL2: Treatment With 90Y-hLL2 IgG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Garden State Cancer Center at the Center for Molecular Medicine and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Garden State Cancer Center at the Center for Molecular Medicine and Immunology</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and deliver
      cancer-killing substances to them without harming normal cells.

      PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody
      therapy in treating patients who have lymphoma or leukemia that has not responded to previous
      chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose and dose limiting toxicity of yttrium Y
      90-labeled humanized anti-CD22 monoclonal antibody LL2(90Y-hLL2 IgG) in patients with B-cell
      malignancies. II. Determine the pharmacokinetics and biodistribution of indium In 111
      humanized LL2 (111In-hLL2 IgG) in these patients. III. Evaluate the immunogenicity of
      repeated injections of 90Y-hLL2 IgG in these patients. IV. Determine whether 90Y-hLL2 IgG
      versus indium In 131 humanized LL2 IgG has a therapeutic advantage based on organ and tumor
      dosimetry obtained with 111In-hLL2 IgG.

      OUTLINE: This is a dose escalation study. Patients are stratified into risk groups (high vs
      low). Patients receive pretherapy imaging with indium In 111 humanized LL2 IgG IV for up to
      30 minutes on days -7 to 0. Patients receive yttrium Y 90-labeled humanized anti-CD22
      monoclonal antibody LL2 (90Y-hLL2-IgG) IV for up to 30 minutes on day 0. Cohorts of 3-6
      patients receive escalating doses of 90Y-hLL2-IgG until the maximum tolerated dose (MTD) is
      determined. The MTD is defined as the dose preceding the dose at which 2 of 3 or 2 of 6
      patients experience dose limiting toxicity. Patients are followed every 2 weeks for 1 month,
      monthly for 2 months, and then every 6 months thereafter.

      PROJECTED ACCRUAL: A total of 18-24 patients will be accrued for this study within 1-2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <primary_completion_date type="Actual">May 2002</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum tolerated dose</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>indium In 111 LL2 IgG</intervention_name>
    <description>single dose, intravenous infusion over 30 minutes</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 epratuzumab</intervention_name>
    <description>single dose, intravenous infusion over 30 minutes</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically or cytologically confirmed B-cell malignancy,
        including B-cell non-Hodgkin's lymphoma or B-cell chronic lymphocytic leukemia, that has
        failed at least one regimen of standard chemotherapy At least 1 confirmed tumor site by
        radiolabeled LL2 IgG No greater than 25% bone or bone marrow involvement No brain
        metastases

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% ECOG 0-2
        Life expectancy: At least 3 months Hematopoietic: WBC at least 3,000/mm3 Granulocyte count
        at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2
        mg/dL AST and alkaline phosphatase less than 1.5 times upper limit of normal (ULN) (except
        for bone involvement) Renal: Creatinine less than 1.5 times ULN Other: Not pregnant Fertile
        patients must use effective contraception during and for 3-6 months after study HIV
        negative No severe anorexia, nausea, or vomiting No other significant concurrent medical
        condition that would interfere with compliance

        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior murine monoclonal antibody therapy
        allowed (if unreactive to yttrium Y 90-labeled humanized anti-CD22 monoclonal antibody LL2
        by HPLC or ELISA test) Chemotherapy: At least 4 weeks since prior chemotherapy Endocrine
        therapy: At least 2 weeks since prior corticosteroids (except for adrenal insufficiency)
        Radiotherapy: At least 4 weeks since prior radiotherapy to the index lesion No prior
        extensive radiotherapy to greater than 25% of bone marrow (except total body irradiation as
        part of bone marrow or stem cell transplantation regimen with engraftment of functional
        marrow (i.e., producing normal peripheral blood counts) No prior maximum tolerated dose
        levels of radiotherapy to critical organs (e.g., lung, liver, or kidney) Surgery: At least
        4 weeks since prior major surgery Other: No other concurrent investigational agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack D. Burton, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Garden State Cancer Center at the Center for Molecular Medicine and Immunology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Garden State Cancer Center</name>
      <address>
        <city>Belleville</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>April 14, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2004</study_first_posted>
  <last_update_submitted>June 21, 2011</last_update_submitted>
  <last_update_submitted_qc>June 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Robert M Sharkey</name_title>
    <organization>GSCC</organization>
  </responsible_party>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>stage I adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage I adult lymphoblastic lymphoma</keyword>
  <keyword>stage I adult Burkitt lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

